Bio-Rad Expands Partnership with a Major Diagnostics Company to Provide InteliQ Portfolio Quality Controls


HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products continues to expand diagnostics company partnerships by providing InteliQ products, a range of barcoded, load-and-go quality control tubes that provide efficiencies in workflow, in addition to Bio-Rad’s Unity QC data management solutions, which help improve a laboratory’s analytical performance.

Today Bio-Rad entered a global partnership with Roche to provide their customers access to Bio-Rad's complete line of InteliQ products and Unity QC data management solutions along with customer training and support services.

The InteliQ products are designed to help streamline a lab's QC workflow with load-and-go efficiency and Unity QC data management solutions that help to reduce turnaround time and increase a lab's overall performance.

"We are proud to extend our partnership with Roche offering their customers access to our InteliQ line of quality controls and Unity QC data management solutions," said Dara Wright, Bio Rad Clinical Diagnostics Group EVP & President. "This agreement further strengthens and expands the relationship between Bio-Rad, the world’s leading QC supplier, and a leading diagnostic solutions provider," she said.

Bio-Rad offers a broad range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing. The company’s Unity QC data management solutions connect large peer groups of test systems and assay methods to the Unity Interlaboratory Program, enabling labs to compare their results in real time with over 25,000 other labs worldwide.

INTELIQ, UNITY and BIO-RAD are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our partnership with Roche and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contact:
Tina Cuccia, Manager
Corporate Communications